Multimodality Treatment by FOLFOX plus HIFU in a Case of Advanced Pancreatic Carcinoma. A Case Report
Context Pancreatic cancer is one of the most aggressive malignant diseases in which the survival rate has not improved in the past 40 years. Case report A fifty-one-year-old male patient with inoperable metastatic pancreatic cancer and low response to chemotherapy with gemcitabine as single therapy underwent palliative high intensity focused ultrasound (HIFU) ablation. Continuing chemotherapy with folinic acid, oxaliplatin and 5-fluorouracil (FOLFOX) was made. Tools, provided by the European Organization for Research and Treatment of Cancer (EORTC) were used to evaluate his quality of life. The Global Health Status improved from 25 to 42 out of 100 and the body mass index (BMI) increased from 14.9 to 18.1 kg/m2. Measured by the visual analog scale, the pain was reduced from 7 to 2 out of 10. Twelve months after the HIFU ablation, CT revealed decreased size of the tumor and liver lesions. Conclusion FOLFOX plus interventional, physical destruction of the primary tumor by HIFU sufficiently improved the quality of life, reduced pancreatic pain and provided better survival in this case.
Image: Hyper-echogenic tumor immediately after HIFU ablation.
Chung-Tsen Hsueh. Pancreatic cancer: current standards, research updates and future directions. Gastrointest Oncol 2011; 2:123-125. [PMID: 22811841]
Ghaneh P, Smith R, Tudor-Smith C, Raraty M, Neoptolemos JP. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008; 34(3): 297-305. [PMID: 17936564]
Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403–2413. [PMID: 9196156]
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al. Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. J Clin Oncol 2013; 31: 23-29. [PMID: 23213101]
Conroy T, Desseigne F, Ychou M et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825. [PMID: 21561347]
Boeck S, Heinemann V. The Role of Second-line Chemotherapy After Gemcitabine Failure in Patients With Advanced Pancreatic Cancer. Future Oncol 2008; 4(1): 41-50. [PMID: 18240999]
Zhang L, Wang ZB. High-intensity focused ultrasound tumor ablation: Review of ten years of clinical experience. Front. Med. China 2010; 4(3): 294–302. [PMID: 21191835]
Orsi F, Zhang L, Arnone P et al. High intensity focused ultrasound (HIFU) ablation: Effective and safe therapy for solid tumors at difﬁcult locations. AJR 2010; 195: W245–W252. [PMID: 20729423]
Sung HY, Jung SE, Cho SH et al. Long-Term Outcome of High-Intensity Focused Ultrasound in Advanced Pancreatic Cancer. Pancreas2011; 40(7): 1080-1086. [PMID: 21926543]
Fayers P, Aaronson NK, Bjordal K, Curran D and Groenvold M on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual (Third edition). Brussels, EORTC Quality of Life Group. 2001; 86 pp.
Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (6): vi85-vi92. [PMID: 21908511]
Kaufman JA, Kinney TB, Streiff MB et al. Guidelines for the Use of Retrievable and Convertible Vena Cava Filters: Report from the Society of Interventional Radiology Multidisciplinary Consensus Conference. J Vasc Interv Radiol 2006; 17: 449–459. [PMID: 16567669]
Wu F, Wang ZB, Lu P et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 2004; 30(9): 1217-22. [PMID: 15550325]
Khokhlova TD, Hwang JH. HIFU for palliative treatment of pancreatic cancer. Journal of Gastrointestinal Oncology 2011; 2(3): 175-184. [PMID: 22811848]
Copyright (c) 2015 Dobromir Dimitrov, Tihomir Andreev, Hyuliya Feradova, Borislav Ignatov, Kunn Zhou, Colin Johnson, Tashko Delijski, Grigor Gortchev, Slavcho Tomov
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.